Page 25 - Pharma Sector

Wanbury surges 5% after USFDA issues Zero observations for Patalganga site

At 9:55 AM, the shares were off highs, trading 2.25 per cent higher at Rs 163.95 per share. In comparison, BSE Sensex was trading 0.16 per cent lower at 77,211.40 levels.

Nepal's drug regulator bans sale of Indian antibiotic over quality issues

Zydus Lifesciences said the reports were 'misleading and erroneous'

Dr Reddy's Laboratories, Warburg Pincus, EQT frontrunners to buy BSV

Advent looking to exit 4 years after it picked up majority stake in biopharma firm

Cipla to invest additional 3 mn euro in mRNA technology company Ethris

The aim is to accelerate Cipla's entry into the mRNA space and deliver innovative mRNA-based therapies, particularly targeting respiratory treatments, to patients in emerging markets

Approval timelines for clinical trial applications back to pre-Covid days

During pandemic, process was faster and nods for Covid-19 trials came in 30 days

Suven Pharma stock rises 6% on nod to acquire Sapala Organics for Rs 230 cr

The surge came after Suven Pharmaceuticals said that it has entered into a definitive agreement to acquire a controlling stake of Sapala Organic for Rs 229.5 crore, in an all cash deal

Venus Remedies up 8% on order win from UNICEF for bacterial infection drug

The uptick in stock price came after the company announced that it has secured an award for its antibiotic product, Ceftriaxone 1 gm, from UNICEF

Torrent Pharma slips 3% after USFDA issues 5 observations for Indrad Unit

The fall came after the United States Food and Drug Administration (USFDA) issued a Form 483 with five observations for the Indrad unit

Pharma's eco pill: Sustainable packaging as new prescription for planet

Merck also revealed that they are investing in renewable energy sources, and half of their Mumbai facility's energy is now sourced from solar panels

IOL Chemicals share price up 6% on bagging CEP certificate for Pantoprazole

Pantoprazole is used for heartburn, acid reflux and gastro-oesophageal reflux disease (GORD)

Weather changes drove Indian pharma market growth to 5.2% in May

Anti-infectives, respiratory therapy areas clock double-digit value growth

Pharma companies step up use of advanced technologies to improve processes

Industry is using AI and digital tools to improve processes and help patients

Dr Reddy's Laboratories eyes acquisitions to drive growth in India

The share of chronic has been steadily rising in the Rs 2 lakh crore domestic pharma market- from 36.4 percent in January 2022 to 38.1 percent in January 2024

Torrent Pharmaceuticals enters into patent licensing agreement with Takeda

Torrent will market Vonoprazan under its own trademark, Kabvie

Aurobindo arm TheraNym inks pact with MSD for biologics manufacturing

This agreement follows previous disclosures by Aurobindo Pharma about expanding its biologics manufacturing facilities and exploring contract manufacturing operations (CMO) for biologicals

Why did investors dump Marksans Pharma shares post Q4 results? Know here

Marksans Pharma's net profit fell 4.5 per cent on a year-on-year (Y-o-Y) basis to Rs 78.3 crore in the March quarter of FY24, from Rs 82 crore in the March quarter of FY23

Deepening presence in Tier-III may be Dr Lal PathLabs' growth pill

Manchanda highlights that the 'white-spaces' for them are going deeper in strong markets

Drugmakers to see FY25 revenue boost in key US market: India Ratings

The world's largest drug market is facing decade-high drug shortages, the research firm said in a note citing data from with Utah Drug Information Service

Aurobindo Pharma Q4 results: PAT rises 79.5% to Rs 908 cr, revenue up 14.8%

The increase in PAT is attributed to expansion into the new markets, product launches and stable pricing

Emcure Pharma, HDT settle legal fight over Covid vaccine technology

The companies said they have signed a long-term agreement to continue collaborating on the development of mRNA-based vaccines and a license that allows Emcure to use HDT's mRNA technology